DIVERSA Technologies
Contact information
- A. Health Biotechnology
- Areas of activity
- Drug delivery
- Drug development
- Gene Therapy
- Therapeutic areas
- Dermatology
- Genetic and rare diseases
- Infectious diseases
- Inflammatory diseases
- Immunology
- Oncology
- Metabolic disorders / Endocrinology
- D. Services
- R&D services
- Nanotechnology and in silico biology
- CRO / CMO / SMO
The main limitation for the arrival of new therapies to the clinic is not the discovery of new targets and therapeutic molecules, but the translation of these molecules into the clinic. Less than 3% of the new molecules that are discovered will make it to clinical stages. The vast majority are discarded in the early stages of research, as they cannot even access the interior of the cell, where 3 out of 4 new molecules have their target.
At DIVERSA, we want to bridge the gap between molecules and patients, between drug discovery and clinical application. We want to create new opportunities to improve patients' quality of life.
Our patented technology of nanometric lipid emulsions can efficiently bind new drug molecules and transport them to their place of action in their therapeutically active form, so that they can be effective and thus generate new opportunities for drug discovery.
We offer our technology as ready-to-use kits. We also offer contract research & development services, and the possibility of establishing non-exclusive licenses for specific indications.
Drug delivery, oncology, osteoarthritis, metabolic syndrome, RNA therapies, cosmetics, and nutraceuticals.